A Phase 2 interventional study of Guadecitabine in Acute Myeloid Leukemia and Myeloid Dysplastic Syndrome, sponsored by Astex Pharmaceuticals, Inc.. Terminated at 21 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-27.
Sponsored by Astex Pharmaceuticals, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Leukemia, Myeloid, Acute by Otsuka Holdings Co., Ltd. — 4 open to participants now, 6 under way, 2 of them phase 3. Leukemia, Myeloid, Acute · Otsuka Holdings Co., Ltd..
Among the 20 studies in Leukemia, Myeloid, Acute by Otsuka Holdings Co., Ltd., this one is the 11th largest by enrollment, is one of 3 that started in 2018, is one of 3 in phase 2, and was the 10th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →4 of the 20 studies in Leukemia, Myeloid, Acute by Otsuka Holdings Co., Ltd. are open now, in 12 countries. Recruiting first, the newest first:
Taiho Oncology, Inc. · Sites in United States, Armenia, Bulgaria and 5 more countries
Ages 18+
Taiho Oncology, Inc. · Sites in United States, Armenia, Bulgaria and 5 more countries
Ages 18+
Taiho Oncology, Inc. · Sites in United States, Canada, Czechia and 7 more countries
Ages 18+
Taiho Oncology, Inc. · Sites in United States, Armenia, Austria and 10 more countries
Ages 18+
By country, each count listing its studies:
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 6 · Phase 3 5
First in 2006; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 42 across the 20 interventional studies. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Astex Pharmaceuticals, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Astex Pharmaceuticals, Inc. is the lead sponsor of 45 studies on the registry; none are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 6 (46%) have results posted.
3 of the studies in Leukemia, Myeloid, Acute by Otsuka Holdings Co., Ltd. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04256317Phase 3Taiho Oncology, Inc.A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | 2027-11-01 |
| NCT04953910Taiho Oncology, Inc.Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment | 2026-12 |
| NCT04953897Taiho Oncology, Inc.Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment | 2026-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 20 studies in Leukemia, Myeloid, Acute by Otsuka Holdings Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter, open-label extension study for participants who participated in a previous Astex-sponsored guadecitabine clinical study [including but not limited to SGI-110-01 (NCT01261312), SGI-110-04 (NCT02348489), SGI-110-06 (NCT02920008), and SGI-110-07 (NCT02907359)].
Participants who were still receiving treatment with guadecitabine and in the opinion of the investigator were still benefitting from treatment at the time of database close of the original study will be eligible to participate in this extension study. Approximately 250 subjects could be enrolled.
Participants will attend clinic visits on Days 1-5 of each 28-day cycle to receive treatment with guadecitabine. Data collection will be limited to treatment exposure, adverse events, concomitant medications, limited laboratory parameters, and survival status.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received guadecitabine, subcutaneous (SC) injection on Days 1-5 of each 28-day cycle at the same dose that they were receiving in the last cycle of their prior study or at a different dose as guided by the dose adjustment guidelines in the prior study protocol.
Drug: Guadecitabine
Guadecitabine
Also known as: SGI-110
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE can therefore be any unfavorable and unintended sign (including a clinically significant abnormal finding in laboratory tests or other diagnostic procedures), symptom, or disease temporally associated with the use of a drug, without any judgment about causality. TEAEs are defined as events that occur or worsen on or after the date of the first study treatment (Cycle 1 Day 1 {C1D1}) until 30 days after the last dose of study treatment or the start of an alternative anti-cancer treatment, whichever occurs first.
Time frame: From the start of study treatment until 30 days after the last dose of study treatment or prior to the participant receiving alternative anticancer therapy, whichever occurs first.
Overall Survival
Overall survival was defined as the number of days from the time of randomization in the prior study to the date of death (regardless of cause). Participants without a documented death date at the time of analysis were censored at the last date known alive. Survival time in days = (earliest of date of death or censoring) - (randomization date in the prior study).
Time frame: From randomization in the prior study to the date of death
Participants were enrolled in the study at 32 study centers in the United States, Spain, Italy, Canada, Japan, France, Germany, Poland, Finland, South Korea, Taiwan, Czech Republic and Australia from 18 July 2018 to 30 November 2020.
| Milestone | Guadecitabine |
|---|---|
| Started | 35 |
| Completed | 0 |
| Not completed | 35 |
| Withdrew: Death | 9 |
| Withdrew: Withdrawal by participant | 7 |
| Withdrew: Study terminated by sponsor | 19 |
Any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE can therefore be any unfavorable and unintended sign (including a clinically significant abnormal finding in laboratory tests or other diagnostic procedures), symptom, or disease temporally associated with the use of a drug, without any judgment about causality. TEAEs are defined as events that occur or worsen on or after the date of the first study treatment (Cycle 1 Day 1 {C1D1}) until 30 days after the last dose of study treatment or the start of an alternative anti-cancer treatment, whichever occurs first.
| Participants | Guadecitabine |
|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 31 |
Overall survival was defined as the number of days from the time of randomization in the prior study to the date of death (regardless of cause). Participants without a documented death date at the time of analysis were censored at the last date known alive. Survival time in days = (earliest of date of death or censoring) - (randomization date in the prior study).
| days | Guadecitabine |
|---|---|
| Overall Survival | 2583.0 (1422.0 to NA) |
Collected over From the start of study treatment until 30 days after the last dose of study treatment or prior to the participant receiving alternative anticancer therapy, whichever occurs first.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Guadecitabine | 9/35 (25.7%) | 20/35 (57.1%) | 0/35 (0%) |
| Event | Guadecitabine |
|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 7/35 |
| PneumoniaInfections and infestations | 6/35 |
| SepsisInfections and infestations | 3/35 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 1/35 |
| AstheniaGeneral disorders | 1/35 |
| Anaphylactic reactionImmune system disorders | 1/35 |
| Bronchopulmonary aspergillosisInfections and infestations | 1/35 |
| Clostridium difficile colitisInfections and infestations | 1/35 |
| GastroenteritisInfections and infestations | 1/35 |
| Herpes zosterInfections and infestations | 1/35 |
Efficacy population included all participants who received any amount of study treatment.
| Age, Continuous(years) | Guadecitabine |
|---|---|
| Mean | 75.3 ± 11.2 |
| Sex: Female, Male(Participants) | Guadecitabine |
|---|---|
| Female | 15 |
| Male | 20 |
| Ethnicity (NIH/OMB)(Participants) | Guadecitabine |
|---|---|
| Hispanic or Latino | 4 |
| Not Hispanic or Latino | 29 |
| Unknown or Not Reported | 2 |
| Race (NIH/OMB)(Participants) | Guadecitabine |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 10 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 24 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2018 to primary completion in Oct 2021, 38 months.
Results were first posted in Apr 2023, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Guadecitabine